Pharmacokinetic evaluation of desogestrel as a female contraceptive

Bibliography

• Pincus G, Garcia CR, Rock J, et al. Effectiveness of an oral contraceptive. Science 1959;30:81-3
   Web of Science ®Google Scholar
• United Nations Department of Economics and Social Affairs Population Division, World Contraceptive Use. 2009. Available from: www.unpopulation.org
   Google Scholar
• Cagnacci A, Ferrari S. Evolution and future of contraception. Minerva Ginecol 2010;62:303-17
   PubMedGoogle Scholar
• Benagiano G, Primiero FM. Seventy-five microgram Desogestrel pill, a new perspective in estrogen-free contraception. Ann NY Acad Sci 2003;997:163-73
   PubMed Web of Science ®Google Scholar
• Viinikka L, Ylikorkala O, Vihko R, et al. Metabolism of a new syntethic progestagen, Org 2969, in female volunteers. Pharmacokinetics after an oral dose. Eur J Clin Pharmacol 1979;15:349-55
   PubMed Web of Science ®Google Scholar
• Hasenack HG, Bosch AMG, Käärk K. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel. Contraception 1986;33:591-7
   PubMed Web of Science ®Google Scholar
• Madden S, Back DJ, Martin AC, Orme ML. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmac 1989;27:295-9
   PubMed Web of Science ®Google Scholar
• Viinikka L. Metabolism of a new synthetic progestagen, Org 2969, by human liver in vitro. J Steroid Biochem 1979;10:353-7
   PubMedGoogle Scholar
• Gentile DM, Verhoven CH, Shimada T, Back DJ. The role of CYP2C in the vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther 1998;287:975-82
   PubMed Web of Science ®Google Scholar
• Korhonen T, Tolonen A, Uusitalo J, et al. The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol 2005;60:69-75
   PubMed Web of Science ®Google Scholar
• Back DJ, Grimmer SF, Shenoy N, Orme ML. Plasma concentrations of 3-keto desogestrel after oral administration of desogestrel and intravenous administration of 3-keto desogestrel. Contraception 1987;35:619-26
   PubMed Web of Science ®Google Scholar
• Verhoven CHJ, Gloudemans RHM, Peeter PAM, et al. Excretion and metabolism of desogestrel in healthy postmenopausal women. J Ster Biochem Molec Biol 2001;78:471-80
   PubMed Web of Science ®Google Scholar
• Verhoven CHJ, Krebbers SFM, Wagenaars GN, Vos RME. In vitro and in vivo metabolism of desogestrel in several species. Drug Metab Dispos 1998;26:927-37
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Pfeffer M, Al-Yaucoub G. Protein binding of the new contraceptive steroids gestodene, 3-keto-desogestrel and ethinyl-estradiol in human serum. J Steroid Biochem 1990;35:313-18
   PubMedGoogle Scholar
• Bjarnadòttir RI, Gottfredsdòttir K, Sigurdardòttir K, et al. A comparative tstudy on the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. BJOG 2001;108:1174-80
   PubMed Web of Science ®Google Scholar
• Pena MA, Sanz E, Francisco S, et al. Randomized, Crossover and single-dose bioequivalence study of two oral desogestrel formulations (film-coated tablets of 75 μg) in healthy female volunteers. Sci Pharm 2012;80:419-31
   PubMedGoogle Scholar
• Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 1989;40:299-312
   PubMed Web of Science ®Google Scholar
• Dragoman M, Petrie K, Torgal A, et al. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception 2013;87:432-6
   PubMed Web of Science ®Google Scholar
• Timmer C, Mulders T. Pharmacokinetics of etonogestrel and ethinylestradiol released from a novel combined contraceptive vaginal ring. Clin Pharmacokinet 2000;39:233-42
   PubMed Web of Science ®Google Scholar
• van den Heuvel M, van Bragt A, Alnabawy A, Kaptein M. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraception formulation: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005;72:168-74
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Torgal AH, Mayeda ER, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. Am J Obstet Gynecol 2012;207:39-45
   PubMedGoogle Scholar
• Roumen FJME, Dieben TOM. Comparison of uterine concentrations of ethinylestradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive. Fertil Steril 2006;85:57-62
   PubMed Web of Science ®Google Scholar
• Huber J. Pharmacokinetics of Implanon®. Contraception 1998;58:85S-90S
   PubMed Web of Science ®Google Scholar
• Diaz S, Pavez M, Moo-Young AJ, et al. Clinical trial with 3-keto desogestrel subdermal implants. Contraception 1991;44:393-408
   PubMed Web of Science ®Google Scholar
• Mornar S, Lingtak-Neander C, Mistretta S, et al. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. Am J Obstet Gynecol 2012;207:110-16
   PubMed Web of Science ®Google Scholar
• Wahl P, Walden R, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308:862-7
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception 2009;79:111-16
   PubMed Web of Science ®Google Scholar
• Guazzelli CA, Berreiros FA, Barbosa R, et al. Extended regimens of the contraceptive vaginal ring versus hormonal oral contraceptives: effect on lipid metabolism. Contraception 2012;85:389-93
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al. Route of administration of contraceptives containing desogestrel/etonogestrel and insulin sensitivity. Contraception 2009;80:34-9
   PubMed Web of Science ®Google Scholar
• Dorflinger LJ. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002;65:47-62
   PubMed Web of Science ®Google Scholar
• Biswas A, Viegas OA, Coeling Bennink HJ, et al. Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception 2001;63:137-41
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Tirelli A, Cannoletta M, et al. Effect on insulin sensitivity of Implanon vs GnRH agonist in women with endometriosis. Contraception 2005;72:443-6
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46S1:S7-S16
   Google Scholar
• Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1998;38:325-32
   Google Scholar
• Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 μg ethinylestradiol and 150 μg desogestrel. Contraception 1995;51:3-12
   PubMed Web of Science ®Google Scholar
• Damey P. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials. Contraception 1993;48:323-37
   PubMed Web of Science ®Google Scholar
• Rice C, Killick S, Hickling D, Coelingh Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel only preparation at three different doses. Hum Reprod 1996;11:737-40
   PubMed Web of Science ®Google Scholar
• Rice CF, Killick SR, Dieben TOM, Coellingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 micrograms and levonorgestrel 30 micrograms daily. Hum Reprod 1999;14:982-5
   PubMed Web of Science ®Google Scholar
• Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. A double blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur J Contracept Reprod Health Care 1998;3:169-78
   PubMedGoogle Scholar
• Mulders TMT, Dieben TOM. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fert Ster 2001;75:865-70
   PubMed Web of Science ®Google Scholar
• Dieben TOM, Roumen FJME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002;100:585-93
   PubMed Web of Science ®Google Scholar
• Mommers E, Blum GF, Gent Thomas G, et al. Nexplanon, a radiopaque etonogetsrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial. Am J Obstet Gynecol 2012;207:388-94
   PubMedGoogle Scholar
• Xu H, Wade JA, Peipert JF, et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012;120:21-6
   PubMed Web of Science ®Google Scholar
• Lawrie TA, Helmerhost FM, Maitra NK, et al. Types of progestogens in combined oral contraception: effectiveness and side-effects (Review). Cochrane Database Syst Rev 2011;5:CD004861
   Google Scholar
• Scala C, Leone Roberti Maggiore U, Remorgida V, et al. Drug safety evaluation of desogestrel. Expert Opin Drug Saf 2013;12:433-44
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Hougaard Nielsen L, Wessel Skovlund C, Lokkengaard E. Venous thrombosis in users of non-oral hoermonal contraception: follow-up study, Denmark 2011-10. BMJ 2012;344:e2990
   PubMed Web of Science ®Google Scholar
• Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. NEJM 2001;345:1787-93
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. NEJM 2012;366:2257-66
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 4th edition 2009, Geneva, Switzerland:1-125
   Google Scholar
• Jordan A. Toxicology of progestogens of implantable contraceptives for women. Contraception 2002;65:3-8
   PubMed Web of Science ®Google Scholar
• Wenzl R, Bennink HC, van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol. Fertil Steril 1993;60:616-19
   PubMed Web of Science ®Google Scholar